Skip to Content

Naramune-2

This page contains information on Naramune-2 for veterinary use.
The information provided typically includes the following:
  • Naramune-2 Indications
  • Warnings and cautions for Naramune-2
  • Direction and dosage information for Naramune-2

Naramune-2

This treatment applies to the following species:
Manufacturer: Boehringer Ingelheim

Canine Parainfluenza-Bordetella Bronchiseptica Vaccine, Modified Live Virus, Avirulent Live Culture

U.S. Vet. Lic. No.: 124

Contents: This product contains the antigens listed above.

Preservative: Neomycin.

Naramune-2 Indications

For vaccination of healthy susceptible dogs and puppies against Canine Upper Respiratory Infection (Canine Cough) caused by canine parainfluenza and Bordetella bronchiseptica. Field studies support the safety of NARAMUNE-2™ when administered to puppies as young as 3 weeks of age.

Dosage and Administration

Rehydration: Rehydrate to desired dose volume with accompanying sterile diluent. For five 0.5 mL doses, reconstitute with 2.5 mL of diluent. For five 1 mL doses, reconstitute with 5 mL of diluent. Shake well and use immediately.

Using aseptic technique, administer entire dose intranasally. Use enclosed applicator tip on hub of syringe in place of syringe needle. Apply new nasal applicator tip for each dog vaccinated. Do not vaccinate puppies under 3 weeks of age. Puppies vaccinated between 3 and 6 weeks of age should be revaccinated at 6 weeks of age. Annual revaccination is recommended.

Precaution(s): Store out of direct sunlight at a temperature between 35-45°F (2-7°C). Use entire contents when first opened. Burn containers and all unused contents.

Caution(s): For intranasal use in dogs only; do not vaccinate dogs parenterally. Anaphylactoid reactions may occur.

Antidote(s): Epinephrine.

Discussion: Description and General Information: NARAMUNE-2™ Canine Parainfluenza Vaccine, Modified Live Virus, Bordetella Bronchiseptica Vaccine, Avirulent Live Culture is designed to be administered intranasally for convenient, rapid prevention of Canine Upper Respiratory Infection (Canine Cough). Both of these organisms are widespread, common etiologic agents of this syndrome which appears as a mild, self-limiting disease involving the trachea and bronchi of dogs of any age. It spreads rapidly among dogs that are closely confined as in hospitals, kennels and pet stores. The disease is highly contagious and is transmitted via the airborne route.

Both of the organisms in NARAMUNE-2™ are avirulent so that they can be safely administered intranasally with little or no symptoms of disease. By instilling these organisms into the nasal passages, it becomes possible for these agents to infect target cells of the nasal-pharyngeal region, mimicking the pathogenesis of natural field infection. A very small percentage of dogs may show sneezing, coughing or nasal discharge for 3-10 days following vaccination. While these are usually temporary symptoms, antibacterial therapy may be indicated.

10423-01 / 10421-01 / 10422-01

Presentation: 20 x 1 dose (1 mL) and 5 dose (5 mL) vials.

NAC No.: 10280791

BOEHRINGER INGELHEIM VETMEDICA, INC.
2621 NORTH BELT HIGHWAY, ST. JOSEPH, MO, 64506-2002
Telephone:   800-325-9167
Fax:   816-236-2717
Website:   www.bevaccinesmart.com
    www.bi-vetmedica.com
    www.biviultraduramune.com
    www.bividollarsandsense.com
    www.bronchi-shieldoral.com
    www.duramunelepto.com
    www.duramunelyme.com
    www.haveweseenyourcatlately.com
    www.metacam.com
    www.mycathasdiabetes.com
    www.productionvalues.us
    www.prrsresearch.com
    www.prozinc.us
    www.vetera-vaccines.com
    www.vetmedin-us.com
    www.yourdogsheart.com
Email:   info@productionvalues.us
Every effort has been made to ensure the accuracy of the Naramune-2 information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.

Copyright © 2016 North American Compendiums. Updated: 2016-10-31

Hide